Findings:

Copper alloy surfaces saw a 99.9% reduction in live bacteria in laboratory tests. In the clinical trials, an 83% reduction in bacteria was seen on the copper alloy components. Infection rates were found to be reduced by 58% in patient rooms with components made of copper.

Funding for the EPA regulatory testing was provided by both the International Copper Association Ltd. (ICA) and Copper Development Association Inc. (CDA).

PubMed Link ( Full-text )